Link Technologies Licenses Exciplex Probe Technology from U of Manchester

Under the terms of the agreement, Link will manufacture and sell diagnostic reagents based on the so-called exciplex technology, which is able to reduce the background fluorescent signal in nucleic acid assays in order to improve the detection sensitivity.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories